Upload
helperforeu
View
216
Download
0
Embed Size (px)
Citation preview
8/14/2019 Pharmaceutical Ind Stu
1/25
Sidra KhalilAisha Akram
Sobia Anwar Dawra
8/14/2019 Pharmaceutical Ind Stu
2/25
History of PharmaceuticalHistory
of Pharmaceutical
Industry of PakistanIndustry
of Pakistan
Pakistan pharmaceutical industry has passed through three mainphases
1948-1971
1972-1991
1991- up till now
8/14/2019 Pharmaceutical Ind Stu
3/25
1.1948-1971
After independence, Pakistan had no pharmaceutical industry andtraders primarily based in India were importing most of themedicines.
The Government of Pakistan established two pharmaceuticalunits named Khurram Chemicals limited (near Islamabad) andAntibiotics Private Limited (in Mianwali) through the PakistanIndustrial Development Board (PIDB).
The growth of pharmaceutical industry started from 1948 andcontinued till 1971. At that time, due to the conducive policy andthe right entrepreneurial spirit, the pharmaceutical industryreached its peak and had a leadership position in Asia.
8/14/2019 Pharmaceutical Ind Stu
4/25
2. 1972-1991
Due to the discriminatory and restrictive registration policy (DrugGeneric Act, 1972), national companies suffered a lot so thatearlier created export markets were lost.
In addition to that, completely manufactured drugs andmedicines were imported largely with the permission of thegovernment, which resulted in large scale flooding of imported
drugs.
8/14/2019 Pharmaceutical Ind Stu
5/25
2. 1992-2008
In this period, the government followed a policy of de-regulationin prices that resulted in free play where the national companiescould fix the same price as multinational companies .
Due to this policy framework, the market share of nationalcompanies grew as compared to multinational companies. Thenational companies grew in size and also exploited possibilities inother regions
8/14/2019 Pharmaceutical Ind Stu
6/25
8/14/2019 Pharmaceutical Ind Stu
7/25
Pakistan pharmaceutical sectorPakistan pharmaceutical sector
overviewoverviewThe pharmaceutical market size is Rs. 70 Billion (US $ 1.2 Billion)approximately. The market for pharmaceuticals in Pakistan has beenexpanding at a rate of around 10-15% since last few years.
Presently the Pharmaceutical industry in Pakistan is producing all themajor pharmaceutical dosage forms. Similarly, there are some special
products e.g immunological, anti-cancer drugs, certain anti-diabetics,antidotes and products manufactured from biotechnology, which arestill being imported, in the finished form.
Only few bulk pharmaceutical raw materials are being manufactured
locally and most of the Pharmaceutical raw materials are beingimported in large quantities from different counters of the world.
At Present 30 multinational Pharmaceutical units are producing theirproducts in Pakistan. 334 national/local units are involved inpharmaceutical manufacturing.
8/14/2019 Pharmaceutical Ind Stu
8/25
Pakistan Health sector overviewPakistan Health sector overviewHealth is priority area of the Government activities. The highcorrelation between the expenditures on health and productivity indeveloping countries like Pakistan is enough to emphasize the
importance of increasing health services as an aid to growth.
Health expenditure during 2007 increased by 35.6 percent to Rs. 53billion. Out of this Rs. 53 billion, largest increase was observed inPunjab (53.3%), followed by NWFP (49.5%), Federal government(23.4%), and Sindh(18.1%).
At Present there are 945 hospitals, 4755 dispensaries, 5349 basichealth units & sub health centers and 903 maternity and child health
centers in Pakistan.
During the fiscal year 2007-08, 43 basic health units and 13 ruralhealth centers have been constructed.While 65 rural health centersand 950 basic health units have been upgraded.
Pakistan Health sector overviewPakistan Health sector overviewPakistan Health sector overviewPakistan Health sector overview
8/14/2019 Pharmaceutical Ind Stu
9/25
80000 Lady Health Workers (LHWs) have been trained and deployedmostly in the rural areas.
Moreover, some 7.5 million children have been immunized and 22million packets of ORS distributed.
Various health programs with a special focus on major public healthproblems have been carried out.These include the national programsfor the prevention and control of tuberculosis, malaria, HIV/AIDS,hepatitis, blindness and program on maternal, neonatal and childhealth etc.
The total outlay on health sector is budgeted at Rs.60 billion (Rs.27.3billion development and Rs. 32.7 billion current expenditure) which isequivalent to 0.6 % of GNP.
total expenditure on health has increased from Rs. 50 billion to Rs.60 billion, of which, Rs. 27 billion have been allocated for
Pakistan Health sector overviewPakistan Health sector overview
8/14/2019 Pharmaceutical Ind Stu
10/25
8/14/2019 Pharmaceutical Ind Stu
11/25
8/14/2019 Pharmaceutical Ind Stu
12/25
ExportsExports
Currently Pakistan is exporting pharmaceutical worth $85 million while the
industry was aiming to expand and this would only be possible when governmentputs a ban on the import of medicine.
The export market is expanding to almost all the continents of the world coveringalmost 40 major countries.
The federal government is making plans to increase exports of thepharmaceutical industry up to US$500 million per annum.
pharmaceutical exports were increasing rapidly at the rate of 20 per cent
annually and the industry was expected to attain 40 to 45 per cent growth inmanufacturing and exports by 2010.
The Middle Eastern, ASEAN and North African countries were lucrative markets forPakistans pharmaceuticals, since Pakistani medicines were recognised for their
high quality.
ExportsExports
Currently Pakistan is exporting pharmaceutical worth $85 million while the
industry was aiming to expand and this would only be possible when governmentputs a ban on the import of medicine.
The export market is expanding to almost all the continents of the world coveringalmost 40 major countries.
The federal government is making plans to increase exports of thepharmaceutical industry up to US$500 million per annum.
pharmaceutical exports were increasing rapidly at the rate of 20 per cent
annually and the industry was expected to attain 40 to 45 per cent growth inmanufacturing and exports by 2010.
The Middle Eastern, ASEAN and North African countries were lucrative markets forPakistans pharmaceuticals, since Pakistani medicines were recognized for their
high quality.
ExportsExports
8/14/2019 Pharmaceutical Ind Stu
13/25
Market Access BarriersMarket Access Barriers
1.Local Manufacture Requirement:
Pharmaceutical research and manufacturers of America (PhRMA)member companies operating in Pakistan face additional hurdles thatdevalue or limit the value of its intellectual property.
Ministry of health insists on local manufacture as a condition ofregistration. It is generally not possible to manufacture all products inPakistan such as products with limited usage and low volume.
Moreover, there are certain products that are manufactured bymember companies at only one site from where they are supplied toother markets and the quantities required for Pakistan are so low thattechnology transfer for local production is not feasible. The result,effectively, is that registration of new chemical entities is often
denied.
Market Access BarriersMarket Access BarriersMarket Access BarriersMarket Access BarriersMarket Access BarriersMarket Access Barriers
8/14/2019 Pharmaceutical Ind Stu
14/25
2. Government Pricing:
The current government pricing system in Pakistan is another majormarket access barrier.
Despite fulfilling all the requirements requested by the healthauthorities to set prices of pharmaceutical products, such as price atthe country of origin, regional prices and the product cost data sheet,the government doesnt consider this information and sets prices at40%-50% less than the original submitted price.
Officials responsible for pricing at ministry of health are mainlyphysicians and dont have the required expertise, technical know howand experience in making this vital decision. Furthermore, prices fornew products are set arbitrarily, rather than on any rational basis.
Arbitrarily low prices have historically caused companies to abandonplans to market products.
Market Access BarriersMarket Access Barriers
8/14/2019 Pharmaceutical Ind Stu
15/25
Drugs Act (1976)Drugs Act (1976)
An Act to regulate the import, export, manufacture, storage, distribution
and sale of drugs.
Drugs Act, 1976 is a Federal legislation with distribution of functionsbetween the Federal Government and Provincial Governments asfollows:-
Federal Government Provincial Government
Manufacture SaleRegistrationsPricingImportExport
8/14/2019 Pharmaceutical Ind Stu
16/25
Under this Act, the Federal Government has laid down the following rulesto carry out various functions entrusted to it under this Act:-
The Drugs (Licensing, Registering and Advertising) Rules 1976. Provide the rules, procedures and conditions for grant of DrugManufacturing Licenses, registration of drugs, promotion to theprofessionals and advertisement of drugs to the general public.
The Drugs (Labeling and Packing) Rules, 1986. - Prescribe themanners in which a registered drug shall be labeled.
The Drugs (Import and Export) Rules, 1976. - Provide proceduresto import the finished drugs and the raw materials. The pharmaceuticalraw materials can be imported by the holders of valid DrugManufacturing Licenses and the registration of the respective drug.
8/14/2019 Pharmaceutical Ind Stu
17/25
The Drugs (Specifications) Rules, 1978. - Provide order ofspecifications which shall be applied to a registered drug.
The Drugs (Federal Inspectors, Federal Drug Laboratory andGovernment Analysts) Rules, 1976. Specify duties of Federal Druginspectors and the procedures of the government analyst.
The Drugs (Appellate Board) Rules 1976. - Provide procedures formaking appeals before the Appellate Board against the decisions of theCentral Licensing and Registration Boards, as the case may be.
The Drugs (Research) Rules, 1978. - Every lincesee is required topay 1% of his gross profit towards a Central Research Fund, administeredby the Federal Government.
8/14/2019 Pharmaceutical Ind Stu
18/25
Industry Academia cooperationIndustry Academia cooperation
The universities of Pakistan were established by the colonial British
government in 1858 so as to produce educated Indians to serve in theexpanding bureaucracy.
Being unattractive, the universities could not attract the mostcompetent students and remained medieval teaching institutions withalmost no research.
Pakistan has a low proportion of well-trained University graduates andeven a lower proportion of technician per million populations relative toneighboring giants as China and India
There are 10 academic institutions recognized by Pakistan Pharmacy
Council for Pharmacy education in Pakistan and at present the academia-pharmaceutical industry collaboration is at its inchoate stages in Pakistan
None of the pharmacy educational institutes has ever filed any patentapplication in Pakistan
Increased collaboration between academia and pharmaceutical industry
8/14/2019 Pharmaceutical Ind Stu
19/25
Industrial partners complain about the unbusiness-like approach of people working
in universities. It is bitter reality that in most of the collaboration efforts, universitieshave difficulty in meeting the timelines agreedIndustry and university partners must be sufficiently flexible as university
regulations and corporate priorities and procedure can have a restrictive influence
on collaborationsThe key individuals need to have the freedom to take the necessary risks and bold
decisions so that the collaboration objectives may be achieved.the positive presence of the company within the university, coupled with direct links
made with students, enhances the companys ability to recruit high caliber
graduates.
8/14/2019 Pharmaceutical Ind Stu
20/25
8/14/2019 Pharmaceutical Ind Stu
21/25
8/14/2019 Pharmaceutical Ind Stu
22/25
1. Glaxo Smith Kline
2. Abbot Knoll
3. Pfizer
4. Aventis
5. Novartis
6. Merck Market
7. Searle
8. Wyeth
9. Roche
10.Bristol Myers Squibb
Pakistans Top 10 IndustriesPakistans Top 10 Industries
8/14/2019 Pharmaceutical Ind Stu
23/25
OpportunitiesOpportunities
Maximum benefits can be reaped if low priced medicines are made
available to the customers.
Pharmaceutical industry must keep itself ready to take on the medicineswhose patents are going to be expired sooner
National companies must go for high quality standards since it is amatter of survival and to stand firm in the cut throat competition
Western companies spend more on the R&D of diseases that are
prevalent globally in both rich and poor countries without taking intoconsideration the diseases of poor counties
Another emerging concept in pharmaceutical manufacturing is contractmanufacturing. Contract manufacturing costs cheaper since it decreases
overheads and the costs associated with fixed assets
8/14/2019 Pharmaceutical Ind Stu
24/25
Problems Faced by IndustryProblems Faced by Industry
Industry is facing difficulties in the production of life-saving medicines
due to gas and electricity load-shedding.
The Pakistani pharmaceutical market remains beset with difficulties.Strict government control over pricing has made many drugsuneconomical, with the result that they either become available only on
the black market at inflated prices, or disappear completely.
In this environment, manufacturers, both local and foreign-owned, haveproved unable to generate the profits needed for capital investment
8/14/2019 Pharmaceutical Ind Stu
25/25
Currently the domestic pharmaceutical industry is operating with low
production volumes, outdated and obsolete machinery and qualitystandards that are not comparable with that of MNCs
The future of the Pharmaceutical Industry lies with the geneticallyengineered medicines butunfortunately there is no infra structure for the
biotechnology in Pakistan.
Political instability, lack of consistency of policies and poor law andorder situation like other sectors has significantly reduced investment inpharmaceutical sector